Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | DRD5 | P21918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29310058 | 0.79 | MAOA (0.39) | DRD2DRD3DRD1DRD5 | |
| SCHEMBL1619374 | 0.75 | MAOA (0.52) | DRD2DRD3DRD1DRD5 | |
| SCHEMBL21362950 | 0.74 | HRH3 (0.46) | DRD2DRD3PNMTDRD1DRD5 | |
| SCHEMBL25101118 | 0.73 | MAOA (0.39) | DRD2DRD3DRD1DRD5 | |
| SCHEMBL12628112 | 0.70 | MAOA (0.55) | KMT2ADRD2DRD3DRD1DRD5 | |
| SCHEMBL20910014 | 0.69 | ALDH1A1 (0.44) | MEN1KMT2AATMDRD2DRD3 | |
| SCHEMBL24253320 | 0.69 | HRH3 (0.38) | DRD2DRD3DRD1DRD5 | |
| SCHEMBL26227089 | 0.69 | DRD1 (0.47) | DRD2DRD3DRD1DRD5 | |
| SCHEMBL14102479 | 0.67 | HRH3 (0.48) | MEN1KMT2ADRD2DRD3PNMT | |
| SCHEMBL21266992 | 0.67 | ASIC3 (0.44) | MEN1KMT2ADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | WEE1, WEE2, DCLRE1B | NMT1 1180/4885MEN1 1813/4885KMT2A 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.